Cubist Pharmaceuticals Newswire

Cubist Pharmaceuticals Newswire

Comprehensive Real-Time News Feed for Cubist Pharmaceuticals.

Results 1 - 20 of 51 in Cubist Pharmaceuticals

  1. Hospital Infection Therapeutics Market to Grow Due to Increasing...Read the original story w/Photo

    Monday Aug 13 | SBWire

    ... stol-Myers Squibb Company, Merck & Co., Inc., GlaxoSmithKline plc, Pfizer, Inc., AstraZeneca plc, and Cubist Pharmaceuticals, Inc. Enquiry for discount on this report -

    Comment?

  2. Concert Pharmaceuticals Inc.'s (CNCE) CEO Roger Tung on Q2 2018 Results - Earnings Call TranscriptRead the original story w/Photo

    Saturday Aug 4 | Seeking Alpha

    Good day ladies and gentlemen and welcome to the Concert Pharmaceuticals' Second Quarter 2018 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

    Comment?

  3. Dow 30 Earnings: Merck Second Quarter 2018Read the original story

    Friday Jul 27 | Value Line

    ... n 2014, the company made three significant acquisitions: Schering-Plough, Idenix Pharmaceuticals, and Cubist Pharmaceuticals. At the time of this article's writing, the author did not have positions in any of the companies mentioned.

    Comment?

  4. A troubling exit: Drug company ends antibiotics researchRead the original story w/Photo

    Sunday Jul 22 | Star Tribune

    A lab at the erstwhile Cubist Pharmaceuticals in 2010. As recent developments involving another drug manufacturer show, maintaining a steady flow of new drugs in development is vital because the bacteria that cause infectious diseases evolve to become less susceptible to treatments.

    Comment?

  5. Cubist Systematic Strategies LLC Decreases Stake in Atlas Air Worldwide Holdings, Inc.Read the original story w/Photo

    Jul 12, 2018 | IntersportsWire

    Cubist Systematic Strategies LLC trimmed its stake in shares of Atlas Air Worldwide Holdings, Inc. by 43.3% in the 1st quarter, Holdings Channel reports. The firm owned 3,788 shares of the transportation company's stock after selling 2,893 shares during the period.

    Comment?

  6. Feuer v. Merck Co IncRead the original story w/Photo

    Jun 1, 2018 | FindLaw

    ... itself and senior management responsible for Merck's acquisition of another pharmaceutical firm, Cubist Pharmaceuticals, Inc. Feuer asserted the acquisition was ill-advised and reckless. He alleged Merck proceeded with the transaction although it ...

    Comment?

  7. ImmusanT Expands Management Team to Strengthen Financial Operations and Accelerate Clinical DevelopmentRead the original story w/Photo

    May 21, 2018 | The Galveston County Daily News

    ... and Alliance Management at Juniper Pharmaceuticals. Previously, Joyce held leadership positions at Cubist Pharmaceuticals, where she was Senior Director, Program and Portfolio Management and at Genzyme, a Sanofi Company, where she was Senior ...

    Comment?

  8. Feds: Biogen, Shire using tactics to thwart genericsRead the original story w/Photo

    May 18, 2018 | Boston Herald

    ... reports of difficulties obtaining Firazyr, which treats hereditary angioedema, a genetic disorder. Cubist Pharmaceuticals and Aegerion were also included on the list. "Shire is committed to developing therapies for rare diseases and specialized ...

    Comment?

  9. Hospital Infection Therapeutics Market Expected to Witness a Sustainable Growth by 2020Read the original story w/Photo

    Apr 20, 2018 | SBWire

    ... stol-Myers Squibb Company, Merck & Co., Inc., GlaxoSmithKline plc, Pfizer, Inc., AstraZeneca plc, and Cubist Pharmaceuticals, Inc. Enquiry for discount on this report - 1280

    Comment?

  10. Trevena Announces Retirement of Maxine Gowen, Ph.D., Effective...Read the original story

    Apr 5, 2018 | Customer Interaction Solutions

    ... in the coming years." Prior to joining Trevena, Ms. Bourdow was vice president of marketing at Cubist Pharmaceuticals, Inc., until its acquisition by Merck & Co., Inc. in January 2015. At Cubist, Ms. Bourdow led launch strategy, marketing, ...

    Comment?

  11. ImmusanT Adds Robert J. Perez to Board of DirectorsRead the original story w/Photo

    Apr 4, 2018 | Business Wire

    Mr. Perez is the first independent member of the ImmusanT Board, which includes representatives from investors ARCH Venture Partners and Vatera Holdings LLC. A longtime executive and advisor in the biopharmaceutical industry, Mr. Perez served as the Chief Executive Officer of Cubist Pharmaceuticals, Inc. at the time the company was acquired by Merck in 2015. Prior to his tenure as CEO, Mr. Perez held multiple roles at Cubist, including President, Chief Operating Officer and Senior Vice President of Sales and Marketing, where he oversaw the launch of CubicinA .

    Comment?

  12. Ex-Merck scientist pays for insider tradingRead the original story

    Mar 5, 2018 | Chemical and Engineering News

    Former Merck & Co. scientist Yang Xie has agreed to pay the U.S. Securities & Exchange Commission a penalty for insider trading related to Merck's 2015 acquisition of Cubist Pharmaceuticals.

    Comment?

  13. Ex-Merck scientist pays for insider tradingRead the original story

    Mar 5, 2018 | Today's Chemist At Work

    ... Securities & Exchange Commission a penalty for insider trading related to Merck's 2015 acquisition of Cubist Pharmaceuticals. Xie, at the time Merck's director of global health outcomes research, bought shares in Cubist soon after learning that ...

    Comment?

  14. Bacteremia Market to Expand with Significant CAGR During 2017 - 2025Read the original story w/Photo

    Mar 7, 2018 | SBWire

    ... a lipopeptide antibiotic is an FDA approved treatment for MRSA bacteria. The drug is manufactured by Cubist Pharmaceuticals, Inc. under brand name CUBICIN. As majority of the treatment involves prescription of generic drugs, the market is mainly ...

    Comment?

  15. Tetraphase Appoints COORead the original story w/Photo

    Mar 2, 2018 | Contract Pharma Breaking News

    ... joining Tetraphase, Mr. Edwards served as senior director of marketing, Gram Negative Franchise, with Cubist Pharmaceuticals, Inc. (later acquired by Merck), where he was responsible for all pre-launch or post-launch marketing activities for ...

    Comment?

  16. SEC Settles With Corporate Insider Who Traded Then LiedRead the original story w/Photo

    Feb 28, 2018 | jdsupra.com

    ... Prior to 2015 one of Merck's main competitors in the area of developing infectious disease drugs was Cubist Pharmaceuticals, Inc. In 2014 Merck considered acquiring Cubist. While the firm was evaluating the question, Mr. Xie analyzed certain Cubist ...

    Comment?

  17. From Whole Foods to Amazon, invasive technology controlling workers is more dystopian than you thinkRead the original story w/Photo

    Feb 24, 2018 | Salon

    ... companies are also taking interest in this kind of mood-observing technology, from Bank of America to Cubist Pharmaceuticals Inc. These developments are part of a larger trend of workers being watched and judged - often at jobs that offer low pay ...

    Comment?

  18. Palo Alto Networks, Inc. (PANW) Analysts See $-0.21 EPS; Guardian...Read the original story w/Photo

    Feb 18, 2018 | Hill Country Times

    Palo Alto Networks, Inc. Analysts See $-0.21 EPS; Guardian Capital LP Has Decreased Suncor Energy New Stake By $1.89 Million Guardian Capital Lp decreased Suncor Energy Inc New stake by 1.49% reported in 2017Q3 SEC filing. Guardian Capital Lp sold 55,454 shares as Suncor Energy Inc New 's stock declined 0.40%.

    Comment?

  19. Dow 30 Earnings: Merck Fourth Quarter 2017Read the original story

    Feb 2, 2018 | Value Line

    ... n 2014, the company made three significant acquisitions: Schering-Plough, Idenix Pharmaceuticals, and Cubist Pharmaceuticals. At the time of this article's writing, the author did not have positions in any of the companies mentioned.

    Comment?

  20. Trevena Promotes Carrie Bourdow to Executive Vice President and Chief Operating OfficerRead the original story

    Feb 2, 2018 | Customer Interaction Solutions

    ... 2015. Prior to joining Trevena, she was vice president of marketing reimbursement, and operations at Cubist Pharmaceuticals, Inc., from 2013 to 2015, where she had responsibility for five acute care hospital pharmaceuticals totaling over $1 billion ...

    Comment?